Pharma Mar SA (XMAD:PHM) Stock Price, Trades & News

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	3.53
Equity-to-Asset	0.65
Debt-to-Equity	0.19
Debt-to-EBITDA	0.66
Interest Coverage	28.29
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.24	Distress Grey Safe
Beneish M-Score	-5.44	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	5.3
	3-Year EBITDA Growth Rate	11.7
	3-Year EPS without NRI Growth Rate	14.6
	3-Year FCF Growth Rate	15.4
	3-Year Book Growth Rate	5.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	36.12
	Future 3-5Y Total Revenue Growth Rate Estimate	20.42

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	55
	9-Day RSI	38.09
	14-Day RSI	34.72
	3-1 Month Momentum %	13.19
	6-1 Month Momentum %	32.36
	12-1 Month Momentum %	25

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.06
	Quick Ratio	2.47
	Cash Ratio	1.88
	Days Inventory	1155.26
	Days Sales Outstanding	52.03
	Days Payable	934.24

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.09
	Dividend Payout Ratio	0.18
	3-Year Dividend Growth Rate	7.2
	5-Year Yield-on-Cost %	1.64
	3-Year Average Share Buyback Ratio	1.4
	Shareholder Yield %	1.98

Profitability Rank

5/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	93.84
	Operating Margin %	22.68
	Net Margin %	29.01
	EBITDA Margin %	27.48
	FCF Margin %	21.94
	OCF Margin %	25.83
	ROE %	34.78
	ROA %	21.17
	ROIC %	35.82
	3-Year ROIIC %	-510.39
	ROC (Joel Greenblatt) %	72.54
	ROCE %	22.8
	Years of Profitability over Past 10-Year	6
	Moat Score	4
	Tariff Resilience Score	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	16.64
	Forward PE Ratio	26.19
	PE Ratio without NRI	16.77
	Shiller PE Ratio	36.16
	Price-to-Owner-Earnings	16.29
	PS Ratio	4.82
	PB Ratio	5.07
	Price-to-Tangible-Book	5.14
	Price-to-Free-Cash-Flow	21.91
	Price-to-Operating-Cash-Flow	18.62
	EV-to-EBIT	18.4
	EV-to-EBITDA	15.82
	EV-to-Forward-EBITDA	19.79
	EV-to-Revenue	4.35
	EV-to-Forward-Revenue	2.13
	EV-to-FCF	19.78
	Price-to-GF-Value	0.88
	Price-to-Projected-FCF	1.78
	Price-to-Median-PS-Value	1.02
	Price-to-Graham-Number	1.96
	Price-to-Net-Current-Asset-Value	9.17
	Price-to-Net-Cash	39.3
	Earnings Yield (Greenblatt) %	5.43
	FCF Yield %	4.56

Financials (Next Earnings Date:2026-07-30 Est.)

Annual Quarterly TTM

XMAD:PHM's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Pharma Mar SA Executives

Details

GF Value™: €83.14

XMAD:PHM

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with PHM. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	263.285
	EPS (TTM) (€)	4.392
	Beta	0.5795
	3-Year Sharpe Ratio	0.98
	3-Year Sortino Ratio	1.88
	Volatility %	28.16
	14-Day RSI	34.72
	14-Day ATR (€)	3.472335
	20-Day SMA (€)	77.9725
	12-1 Month Momentum %	25
	52-Week Range (€)	64 - 105.2
	Shares Outstanding (Mil)	17.31

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Pharma Mar SA Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Pharma Mar SA Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-10-30	In 122 days
Second quarter earnings conference call for 2026	2026-07-31 13:00	In 32 days
Second quarter earnings results for 2026	2026-07-30	In 30 days
General meeting for 2025	2026-06-30 12:00	In 1 day
General meeting for 2025	2026-06-18 12:00	68.70 (-0.15%)
First quarter earnings results for 2026	2026-04-29	98.65 (+1.81%)
Fourth quarter earnings conference call for 2025	2026-02-27 13:30	79.05 (-0.13%)
Annual report for 2025	2026-02-27	79.05 (-0.13%)
Fourth quarter earnings results for 2025	2026-02-27	79.05 (-0.13%)
Third quarter earnings results for 2025	2025-10-30	73.60 (+0.14%)

Show

Entries

Pharma Mar SA Frequently Asked Questions

What is Pharma Mar SA(XMAD:PHM)'s stock price today?

The current price of XMAD:PHM is €73.10. The 52 week high of XMAD:PHM is €105.20 and 52 week low is €64.00.

When is next earnings date of Pharma Mar SA(XMAD:PHM)?

The next earnings date of Pharma Mar SA(XMAD:PHM) is 2026-07-30 Est..

Does Pharma Mar SA(XMAD:PHM) pay dividends? If so, how much?

The Dividend Yield % of Pharma Mar SA(XMAD:PHM) is 1.09% (As of Today), Highest Dividend Payout Ratio of Pharma Mar SA(XMAD:PHM) was 13.54. The lowest was 0.06. And the median was 0.21. The Forward Dividend Yield % of Pharma Mar SA(XMAD:PHM) is 0%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
	Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants	2022-01-11
	PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With AplidinÂ® (Plitidepsin) for the Treatment of Patients With COVID-19	2020-04-28
	Sylentis, PharmaMar Group, Announces the End of Patient Recruitment for its HELIX Trial	2018-10-19
	PharmaMar Presents the Overall Survival Data From the Phase I/II Study of lurbinectedin in Combination With Doxorubicin for Relapsed Small Cell Lung Cancer	2018-09-24
	PharmaMar is Announcing its Intention to Conduct a Registered Public Offering of American Depositary Shares	2018-09-07
	PharmaMar Will Present the Results of the Phase I/II Study With Lurbinectedin in Combination With Doxorubicin in Relapsed Small-cell Lung Cancer During the IASLC World Conference	2018-09-06
	The U.S. Food and Drug Administration (FDA) Has Granted Orphan Drug Designation to PharmaMar's Lurbinectedin	2018-08-03
	PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment	2018-07-31
	PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of YondelisÂ® in the Nordic Countries and Eastern Europe	2018-07-27
	PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for ZepsyreÂ® in Japan	2018-06-26

10/Page

Articles on Pharma Mar SA

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.